Showing results (41-50 of 58) with videos related to
Sort By:
Pageof 6
Chemmedchem|September 29, 2011
Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirineStefano Alcaro, Claudia Alteri, Anna Artese, et al.The Journal of Antimicrobial Chemotherapy|January 25, 2020
Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and ItalyCathia Soulie, Maria Mercedes Santoro, Alexandre Storto, et al.AIDS Research and Human Retroviruses|May 30, 2008
Plasma HIV RNA decline and emergence of drug resistance mutations among patients with multiple virologic failures receiving resistance testing-guided HAARTValerio Tozzi, Rita Bellagamba, Filippo Castiglione, et al.Journal of Medical Virology|March 24, 2006
Clinical and genotypic correlates of mutation K65R in HIV-infected patients failing regimens not including tenofovirMaria Paola Trotta, Sandro Bonfigli, Francesca Ceccherini-Silberstein, et al.Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|May 9, 2018
Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatmentDaniele Armenia, Mauro Zaccarelli, Vanni Borghi, et al.Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|July 30, 2016
Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNAMauro Zaccarelli, Maria Mercedes Santoro, Daniele Armenia, et al.Journal of Clinical Microbiology|July 14, 2017
Comparative Evaluation of Subtyping Tools for Surveillance of Newly Emerging HIV-1 StrainsLavinia Fabeni, Giulia Berno, Joseph Fokam, et al.Pharmaceuticals (Basel, Switzerland)|April 23, 2022
Virological and Immunological Outcomes of an Intensified Four-Drug versus a Standard Three-Drug Antiretroviral Regimen, Both Integrase Strand Transfer Inhibitor-Based, in Primary HIV InfectionAnnalisa Mondi, Carmela Pinnetti, Patrizia Lorenzini, et al.Plos One|January 24, 2013
The genotypic false positive rate determined by V3 population sequencing can predict the burden of HIV-1 CXCR4-using species detected by pyrosequencingValentina Svicher, Valeria Cento, Gabriella Rozera, et al.Journal of Global Antimicrobial Resistance|July 6, 2022
Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practiceDaniele Armenia, Federica Forbici, Ada Bertoli, et al.Pageof 6